Emerging roles for triggering receptor expressed on myeloid cells receptor family signaling in inflammatory diseases

Christopher J. Pelham, Devendra K. Agrawal

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Innate immune receptors represent important therapeutic targets for inflammatory disorders. In particular, the Toll-like receptor (TLR) family has emerged as a promoter of chronic inflammation that contributes to obesity, insulin resistance and atherosclerosis. Importantly, triggering receptor expressed on myeloid cells-1 (TREM-1) has been characterized as an 'amplifier' of TLR2 and TLR4 signaling. TREM-1- and TREM-2-dependent signaling, as opposed to TREM-like transcript-1 (TLT-1 or TREML1), are mediated through association with the transmembrane adaptor DNAX activation protein of 12 kDa (DAP12). Recessive inheritance of rare mutations in DAP12 or TREM-2 results in a disorder called polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, and surprisingly these subjects are not immunocompromised. Recent progress into the roles of TREM/DAP12 signaling is critically reviewed here with a focus on metabolic, cardiovascular and inflammatory diseases. The expanding repertoire of putative ligands for TREM receptors is also discussed.

Original languageEnglish
Pages (from-to)243-256
Number of pages14
JournalExpert Review of Clinical Immunology
Volume10
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Myeloid Cells
Proteins
Toll-Like Receptors
Insulin Resistance
Atherosclerosis
Cardiovascular Diseases
Obesity
Ligands
Inflammation
Mutation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Emerging roles for triggering receptor expressed on myeloid cells receptor family signaling in inflammatory diseases. / Pelham, Christopher J.; Agrawal, Devendra K.

In: Expert Review of Clinical Immunology, Vol. 10, No. 2, 02.2014, p. 243-256.

Research output: Contribution to journalReview article

@article{7bcfb2969e5a40cb991abf0888396efe,
title = "Emerging roles for triggering receptor expressed on myeloid cells receptor family signaling in inflammatory diseases",
abstract = "Innate immune receptors represent important therapeutic targets for inflammatory disorders. In particular, the Toll-like receptor (TLR) family has emerged as a promoter of chronic inflammation that contributes to obesity, insulin resistance and atherosclerosis. Importantly, triggering receptor expressed on myeloid cells-1 (TREM-1) has been characterized as an 'amplifier' of TLR2 and TLR4 signaling. TREM-1- and TREM-2-dependent signaling, as opposed to TREM-like transcript-1 (TLT-1 or TREML1), are mediated through association with the transmembrane adaptor DNAX activation protein of 12 kDa (DAP12). Recessive inheritance of rare mutations in DAP12 or TREM-2 results in a disorder called polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, and surprisingly these subjects are not immunocompromised. Recent progress into the roles of TREM/DAP12 signaling is critically reviewed here with a focus on metabolic, cardiovascular and inflammatory diseases. The expanding repertoire of putative ligands for TREM receptors is also discussed.",
author = "Pelham, {Christopher J.} and Agrawal, {Devendra K.}",
year = "2014",
month = "2",
doi = "10.1586/1744666X.2014.866519",
language = "English",
volume = "10",
pages = "243--256",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Emerging roles for triggering receptor expressed on myeloid cells receptor family signaling in inflammatory diseases

AU - Pelham, Christopher J.

AU - Agrawal, Devendra K.

PY - 2014/2

Y1 - 2014/2

N2 - Innate immune receptors represent important therapeutic targets for inflammatory disorders. In particular, the Toll-like receptor (TLR) family has emerged as a promoter of chronic inflammation that contributes to obesity, insulin resistance and atherosclerosis. Importantly, triggering receptor expressed on myeloid cells-1 (TREM-1) has been characterized as an 'amplifier' of TLR2 and TLR4 signaling. TREM-1- and TREM-2-dependent signaling, as opposed to TREM-like transcript-1 (TLT-1 or TREML1), are mediated through association with the transmembrane adaptor DNAX activation protein of 12 kDa (DAP12). Recessive inheritance of rare mutations in DAP12 or TREM-2 results in a disorder called polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, and surprisingly these subjects are not immunocompromised. Recent progress into the roles of TREM/DAP12 signaling is critically reviewed here with a focus on metabolic, cardiovascular and inflammatory diseases. The expanding repertoire of putative ligands for TREM receptors is also discussed.

AB - Innate immune receptors represent important therapeutic targets for inflammatory disorders. In particular, the Toll-like receptor (TLR) family has emerged as a promoter of chronic inflammation that contributes to obesity, insulin resistance and atherosclerosis. Importantly, triggering receptor expressed on myeloid cells-1 (TREM-1) has been characterized as an 'amplifier' of TLR2 and TLR4 signaling. TREM-1- and TREM-2-dependent signaling, as opposed to TREM-like transcript-1 (TLT-1 or TREML1), are mediated through association with the transmembrane adaptor DNAX activation protein of 12 kDa (DAP12). Recessive inheritance of rare mutations in DAP12 or TREM-2 results in a disorder called polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, and surprisingly these subjects are not immunocompromised. Recent progress into the roles of TREM/DAP12 signaling is critically reviewed here with a focus on metabolic, cardiovascular and inflammatory diseases. The expanding repertoire of putative ligands for TREM receptors is also discussed.

UR - http://www.scopus.com/inward/record.url?scp=84893072503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893072503&partnerID=8YFLogxK

U2 - 10.1586/1744666X.2014.866519

DO - 10.1586/1744666X.2014.866519

M3 - Review article

C2 - 24325404

AN - SCOPUS:84893072503

VL - 10

SP - 243

EP - 256

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 2

ER -